Jerry St Peter to spearhead NicOx expansion in US
Aims to build an international ophthalmology company
St Peter has extensive knowledge of the ophthalmology market in the US. Most recently, he developed the commercial unit of Inspire Pharmaceuticals, an ophthalmology focused company acquired by Merck & Co for US$430m in May 2011.
In collaboration with NicOx’s European headquarters, St Peter will be responsible for identifying and evaluating North American opportunities that can be exploited globally to build NicOx’s late-stage ophthalmic portfolio. He will also lead the development of NicOx’s US ophthalmology business.
NicOx announced earlier this week that it had acquired 11.8% of the shares of Altacor, a privately held ophthalmology company based in the UK, and entered into an exclusive option agreement to acquire the remaining shares.
Michele Garufi, chairman and ceo of NicOx, said: ‘Jerry has been working with NicOx as a consultant for the past five months, helping us in the ongoing evaluation of a number of ophthalmology companies and products. He will be a key asset in the creation and future expansion of our presence in the US as we work towards delivering our strategy of building an international ophthalmology company.’
St Peter joined Inspire in 2003 and held the positions of senior vice president, Ophthalmology Business Unit, svp, sales and managed markets and vp of sales.
Prior to joining Inspire, St Peter held a number of leadership positions for Muro Pharmaceutical, a private ophthalmic, pulmonary, asthma and allergy specialist pharmaceutical company.
You may also like
                                                            Manufacturing
                                                        
                                
                                                                            
                                                                    
                                
                    Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025
The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
                                                                    
                                
                            
                        
                                                            Pharmaceutical
                                                        
                                
                                                                            
                                                                    
                                
                    Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit
As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
                                                                    
                                
                            
                        
                                                            Manufacturing
                                                        
                                
                                                                            
                                                                    
                                
                    Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
                                                                    
                                
                            
                        
                                                            Manufacturing
                                                        
                                
                                                                            
                                                                    
                                
                    Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio